Company intelligence / Profile preview

Kira Biotech

Brisbane (Fortitude Valley), Queensland, Australiakirabiotech.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Kira Biotech has developed novel monoclonal antibodies targeting activated immune cells, particularly anti-CD83 antibodies. The company’s approach aims to induce immune tolerance and restore homeostasis in patients with autoimmune or immune-related conditions. As of the latest information, their lead assets are at the preclinical stage. No published clinical results yet.

Therapeutic areas: Immunology
Modalities: Monoclonal antibodiesImmunomodulatory compounds
Industry: Biotech

Drug pipeline

1 asset

KB312

Preclinical

Beyond the preview

Go deeper on Kira Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kira Biotech.

Explore the full profile